OBI Entered into an Exclusive License Agreement with Odeon for OBI-999 and OBI-833 to Treat Cancer in China, Hong Kong and Macau
- OBI to receive $12M as an equity equivalent upon signing & ~$188M as development & commercialization milestones along with royalties & also obtains global rights to OBI-999 & OBI-833 (Ex- China, Hong Kong & Macao)
- Odeon gets exclusive rights to develop & commercialize OBI-999 & OBI-833 for cancer in China, Hong Kong & Macao & will lead all development, regulatory & commercialization costs of OBI-999 & OBI-833
- In the P-I study, OBI-999 showed an excellent safety & PK profile while OBI-833 also showed a favorable safety profile & generated detectable anti-Globo H IgM and IgG responses along with durable stable disease status for NSCLC patients co-treated with an EGFR-TKI
Ref: PR Newswire | Image: The Pharma Letter
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].